Inflammatory Linear Verrucous Epidermal Nevus is a rare disease of the skin that presents as multiple, discrete, red papules that tend to coalesce into linear plaques that follow the Lines of Blaschko. The plaques can be slightly warty (psoriaform) or scaly (eczema-like). ILVEN is caused by somatic mutations that result in genetic mosaicism. There is no cure, but different medical treatments can alleviate the symptoms. Classification
ILVEN is a condition that normally only affects one side of the body (unilateral). Usually the left side of patients is affected. The condition is persistent and forms along characteristic lines. It usually appears on an extremity in infancy or childhood. Altman and Mehregan described six characteristic features of ILVEN: (1) early age of onset, (2) predominance in females (4:1 female-male ratio), (3) frequent involvement of the left leg, (4) pruritus, or "itchiness" (5) marked refractoriness to therapy, and (6) a distinctive psoriasiform and inflammatory histologic appearance. Genetics
Most cases are sporadic, but a familial case, with the condition occurring in a mother and her daughter, has been described.It also has been proposed that activation of an autosomal dominant lethal mutation that survives by mosaicism may be the cause of the lesions. The mutated cells may survive in the due to proximity of normal cells. Another theory is that retrotransposable elements may be the cause of all skin conditions along the Lines of Blashko.
Amlodipine/celecoxib, sold under the brand name Consensi, is a fixed-dose combination medication used to treat both hypertension and osteoarthritis at the same time in adults. It contains amlodipine besylate and celecoxib. It is taken by mouth.The most common side effects include edema, abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and rash.It was approved for medical use in the United States in May 2018. Medical uses
Amlodipine/celecoxib is indicated for use in adults for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. History
Amlodipine/celecoxib was approved for use in the United States in May 2018. References
External links
"Amlodipine mixture with celecoxib". Drug Information Portal. U.S. National Library of Medicine.